AAmadix
Amadix is a Spanish molecular diagnostics company developing blood-based (liquid biopsy) tests combined with AI and clinical data for early cancer detection, before symptoms appear. Its product line includes PreveCol (colorectal cancer and advanced adenoma), Diagnolung (lung cancer) and Pancreadix (pancreatic cancer); PreveCol received FDA Breakthrough Device Designation in 2024. Founded in 2010 and headquartered in Valladolid with an office in Madrid, the company has raised financing from Spanish/European VC funds and received a €15M EIB loan in February 2025 to fund US clinical validation and international expansion.
SectorsOncology diagnostics, Liquid biopsy, Precision medicine, Healthtech, AI diagnostics
Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing
Founders
R
Rocío Arroyo
Founder & CEO
Global models 5
GGRAIL
United States · grail.com ↗
Blood-based multi-cancer early detection test using genomic sequencing, the closest large-scale global comparable to Amadix's liquid biopsy early cancer detection model.
$2.0B+Comparable
FFreenome
United States · www.freenome.com ↗
Develops blood tests combining multiomics and AI/machine learning for early cancer detection, directly paralleling Amadix's biomarker-plus-AI approach.
$1.3B+Comparable
GGuardant Health
United States · guardanthealth.com ↗
Liquid biopsy company offering blood-based cancer screening and monitoring tests, same core blood-test diagnostics model as Amadix, later went public.
~$550M (pre-IPO VC)Comparable
DDELFI Diagnostics
United States · delfidiagnostics.com ↗
Uses AI-driven analysis of cell-free DNA fragmentation patterns in blood for early multi-cancer detection, a close model match to Amadix's blood-plus-AI diagnostics.
$275MComparable
T
Thrive Earlier Detection
United States · www.thrivedetect.com ↗
Developed a blood test combining genomic biomarkers and imaging/AI for multi-cancer early detection, closely mirroring Amadix's diagnostic model before being acquired.
$257M (acquired by Exact Sciences for $2.15B)Comparable
In the same niche 48 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 11
Open as list →C
CRB Health Tech
www.crbinverbio.com
EEuropean Investment Bank
www.eib.org
IInveready
www.inveready.com
CCapital Cell
capitalcell.com
CCentro para el Desarrollo Tecnológico y la Innovación
www.cdti.es
DDozen Investments
thecrowdangel.com
S
SODICAL
www.sodical.es
C
Clave Capital
www.clave.es
EEIC Fund
eic.ec.europa.eu
E
EIT Health
eithealth.eu
A
Alentia
Funding rounds 7
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-02-10 | Venture Debt | €15M | European Investment Bank |
| 2021-09-15 | Series B (estimated) | approximately €1.9M |
Lead not disclosed
+1 more
|
| 2020-10-27 | Series B (estimated) | €532K |
CRB Inverbío
+1 more
|
| 2019-11-28 | Series B (estimated) | €3.2M |
Lead not disclosed
+5 more
|
| 2018-10-09 | Series A | €1.5M |
Lead unknown
+1 more
|
| 2016-12 | Series A | €1.6M |
Lead not disclosed
+2 more
|
| 2013-02-08 | Seed | €2M |
CRB Inverbío
+1 more
|
News 7
Open as list →| Published | Article |
|---|---|
| 2026-02-06 |
Amadix selected as one of the 8 winners of ACCIÓN, the innovative healthcare project accelerator by AstraZeneca, Wayra and Kunsen ↗
Capital-Riesgo.es
2026-02-06 |
| 2025-11-05 |
Amadix: Advancing early cancer detection with cutting-edge diagnostics ↗
EIC Scaling Club
2025-11-05 |
| 2025-02-11 |
Spain: EIB finances with €15 million Amadix to develop innovative diagnostic tests for early cancer detection ↗
European Investment Bank
2025-02-11 |
| 2024-09-27 |
Amadix signs an agreement with MD Anderson Madrid so that its patients can benefit from PreveCol® ↗
Amadix (press release)
2024-09-27 |
| 2024-01-23 |
FDA grants breakthrough device designation to Amadix's blood test for colorectal cancer ↗
Healio
2024-01-23 |
| 2023-12-19 |
Rocío Arroyo, CEO of Amadix, new president of AseBio ↗
AseBio
2023-12-19 |
| 2023-11-21 |
CEMTRO clinic incorporates PreveCol® blood test for early colorectal cancer detection ↗
Amadix (press release)
2023-11-21 |